We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Midatech Pharma Plc | LSE:MTPH | London | Ordinary Share | GB00BNGF1L75 | ORD GBP0.02 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 18.00 | 17.00 | 19.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
09/9/2020 09:24 | You'll never see these low levels again. | hodhasharon | |
07/9/2020 10:33 | Existing week .I am long and adding | shujja1 | |
07/9/2020 09:44 | Yup total nutcase. Who knows? With this one. Maybe well get a better idea tomorrow. | escapetohome | |
07/9/2020 09:38 | Ditto. Small size, though. This one is a little mad. | chucko1 | |
07/9/2020 09:15 | Im back in | escapetohome | |
03/9/2020 09:58 | MTPH strong buy signal.Big pharma Jv update imminent.We can test 100p again.Great entry price | 36jay | |
30/8/2020 22:07 | RNS Number : 6125T Midatech Pharma PLC 21 July 2020 21 July 2020 Midatech Pharma PLC ("Midatech" or the "Company") Midatech adds to collaborative business model for the Q-Sphera platform Midatech Pharma's next generation drug delivery technologies to be applied to new modalities in collaboration with a European pharmaceutical company. Cardiff, UK, 21 July 2020: Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines announces it has entered into a research collaboration for the Q-Sphera platform with a European affiliate of a global pharmaceutical company. Within the multi-project collaboration, Midatech will deploy its in-house expertise and proprietary drug delivery platforms towards assets nominated by the pharmaceutical company. The feasibility studies may establish the application of the Q-Sphera platform to new modalities in drug delivery. Novel assets and products arising from the collaboration will be the property of the pharmaceutical company and in the event that the feasibility study is successful, the pharmaceutical company would be required to enter into a licence agreement to use the Q-Sphera platform. Following announcement of the first research agreement for the Q-Sphera platform on 8 June 2020, this second Pharmaceutical collaboration further builds upon Midatech's dual business model to develop an internal portfolio of differentiated, sustained release products in parallel to enabling access to the technology by strategic collaborators to best exploit the full potential of the Q-Sphera platform, and potentially broaden its application to new therapeutic areas and modalities. Stephen Stamp, CEO of Midatech, said: "This collaboration with a highly reputable company further builds upon Midatech's mission to use our expertise and established capabilities to continually innovate and improve our technologies. By furthering our collaborative business model, we believe we can enable the unique qualities of this technology to reach beyond our own internal development pipeline for the benefit of all patients." This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 | bidmsa | |
28/8/2020 11:58 | That is a US $Dollar price which has to be converted in to uk £pound price before you divide it by 5. | bidmsa | |
28/8/2020 11:33 | According to US price we should be around 50p to 55p 1 adr equally 5 uk shares | abconline | |
28/8/2020 07:58 | 28 August 2020 Midatech Pharma PLC ("Midatech" or the "Company") Notice of Interim Results Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, will announce its interim results for the six months ended 30 June 2020 on 10 September 2020. The Company will host an investor conference call at 2.00pm on the day of the results, details of which will be announced in due course. | eggbird | |
27/8/2020 13:28 | News this afternoon? The RNS pattern has painted itself in the chart. | hodhasharon | |
27/8/2020 11:10 | The RNS from the seller the other day clearly say that the holding is now below 3%. not 100% out as some are saying. This share is still offered. | wilsonst1 | |
26/8/2020 13:36 | midatech 1 volume trade now showing on Pre US Market opening. | bidmsa | |
26/8/2020 12:49 | Back to 90p....this is getting boring. | hodhasharon | |
26/8/2020 12:49 | getting rid of the shorters & then let it take off. | bidmsa | |
26/8/2020 11:47 | midatech 1 volume trade news is coming. | bidmsa | |
25/8/2020 10:26 | entering into a research collaboration for the Q-Sphera platform with a European affiliate of a global pharmaceutical company. regarding to the above which pharmaceutical company is it. | bidmsa | |
22/8/2020 09:14 | Yes there is no way you can deal ‘at best’ on the spike, so i ususally set. A limit order 1 or 2 p below , and it ususally goes through, for say 10,000 shares. | escapetohome | |
22/8/2020 09:12 | Yup a very spiky share, you can be sure i will buy back at 30 - 33 p , should that opportunity become available once more. | escapetohome |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions